Content Spotlight
Podcast: MilliporeSigma says education vital to creating unbreakable chain for sustainability
MilliporeSigma discusses the importance of people, education, and the benefits of embracing discomfort to bolster sustainability efforts.
Allogene has confirmed it is building a 118,000 square foot cell therapy manufacturing facility in Newark, California to support its AlloCAR T candidates.
Last month, Allogene Therapeutics revealed to BioProcess Insider its intentions to establish a manufacturing facility in the San Francisco Bay area.
The firm did not provide projections at the time, but has now said it has entered a lease agreement at a site in Newark, California to build a 118,000 square foot cell therapy manufacturing facility.
Image: iStock/the_guitar_mann
“This manufacturing facility and continued build out of our in-house process development and characterization capability will allow us to advance manufacturing and secure the supply of our AlloCAR T therapies,” Alison Moore, CTO of Allogene said in a statement.
Allogene, founded last year by former Kite Pharma executives, aims to bring allogeneic chimeric antigen receptor (CAR) T-cell therapies to the market.
According to the firm, its AlloCAR T therapies are made using T cells harvested from healthy donors that are then engineered to express CARs designed to recognize certain cell surface proteins expressed on hematologic or solid tumors. Genes within T cells are then edited to reduce the risk of graft versus host disease and allogeneic rejection.
Lead candidate UCART19 is being co-sponsored by Servier and is one of a number of partnered CAR-T programs Allogene taken over from Pfizer in April 2018. Pfizer traded its rights to UCART19 and 16 preclinical CAR-T candidates for a 25 percent stake in Allogene.
You May Also Like